| Overview |
| bs-9185R-Biotin |
| VGLL4 Polyclonal Antibody, Biotin Conjugated |
| WB, IHC-P |
| Human, Mouse, Rat |
| Specifications |
| Biotin |
| Rabbit |
| KLH conjugated synthetic peptide derived from human VGLL4 |
| 201-290/290 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 9686 |
| Q14135 |
| Transcription cofactor vestigial like protein 4; Vestigial like protein 4; VGL 4; VGLL4; VGLL4_HUMAN. |
| The transcriptional enhancer factor-1 (TEF-1) family of transcription factors regulate tissue-specific gene expression in muscle and placenta. The mechanism whereby TEF-1 confers tissue specificity depends largely on the interaction of TEF-1 with tissue-specific cofactors. Transcription cofactor Vgl-4 (vestigial-like protein 4) is a 290 amino acid nuclear protein that interacts with TEF-1 and MEF-2. Vgl-4 is the only member of the vestigial-like family that is expressed in heart. Overexpression of Vgl-4 in cardiac myocytes interferes with basal expression and ?-adrenergic receptor-dependent activation of a TEF-1 dependent skeletal ?actin promoter. This suggests that Vgl-4 counteracts ?-adrenergic activation of gene expression in cardiomyocytes. There are two isoforms of Vgl-4 that are produced as a result of alternative splicing events. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
Powered by Bioz